ALK-Abelló
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
ALK | CO
Overview
Corporate Details
- ISIN(s):
- DK0061802139
- LEI:
- 529900SGCREUZCZ7P020
- Country:
- Denmark
- Address:
- Bøge Alle 6-8, 2970 Hørsholm
- Website:
- https://www.alk.net
- Sector:
- Manufacturing
Description
ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-03-21 16:57 |
Grant of share options and performance shares to members of the Board of Manage…
|
English | HTML • 4.4 KB | ||
| 2019-03-21 16:57 |
Grant of share options and performance shares to members of the Board of Manage…
|
English | PDF • 33.1 KB | ||
| 2019-03-04 16:53 | Danish | HTML • 16.4 KB | |||
| 2019-03-04 16:53 | English | HTML • 16.7 KB | |||
| 2019-03-04 16:53 |
Report on transactions with ALK-Abelló A/S B-shares and associated securities b…
|
English | PDF • 35.2 KB | ||
| 2019-03-04 16:53 |
Report on transactions with ALK-Abelló A/S B-shares and associated securities b…
|
English | PDF • 35.1 KB | ||
| 2019-02-07 07:32 | English | HTML • 5.1 KB | |||
| 2019-02-07 07:32 | English | PDF • 6.6 MB | |||
| 2019-02-07 07:32 |
ALK releases its annual report 2018
|
English | PDF • 6.6 MB | ||
| 2019-02-07 07:32 |
ALK releases its annual report 2018
|
English | HTML • 5.4 KB | ||
| 2019-01-15 14:22 | English | HTML • 5.0 KB | |||
| 2019-01-15 14:22 | English | PDF • 37.0 KB | |||
| 2019-01-15 14:21 |
Large-scale paediatric SLIT-tablet trial meets primary endpoint, confirming pot…
|
English | PDF • 38.2 KB | ||
| 2019-01-15 14:21 |
Large-scale paediatric SLIT-tablet trial meets primary endpoint, confirming pot…
|
English | HTML • 5.0 KB | ||
| 2018-12-14 14:33 | English | HTML • 3.3 KB |
Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALK-Abelló
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALK-Abelló via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
